EP 1467994 A1 20041020 - PTERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF
Title (en)
PTERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF
Title (de)
PTERIDINDERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND IHRE VERWENDUNG
Title (fr)
DERIVES DE PTERIDINE, PROCEDE DE PRODUCTION DE CES DERIVES ET LEUR UTILISATION
Publication
Application
Priority
- DE 10202468 A 20020123
- EP 0300676 W 20030123
Abstract (en)
[origin: WO03062240A1] The invention relates to compounds of general formula (I), in which R1 represents a piperazino, p-phenylendiamine, 2,5-diazabicyclo-2.2.1-heptane, 2,5-diazabicyclo-2.2.2-octane, or 3,8-diazabicyclo-3.2.1-octane residue, each of which can be substituted with at least one substituent, R2, R4, which are identical, represent a pyrrolidino, thiazolidine, oxazolidine, or imidazolidine residue, each of which can be substituted with at least one substituent, R3 represents an alkyl, alkoxy, alkylmercapto, or alkylamino residue, each of which can be substituted with at least one substituent, and the acid addition salts thereof. Said pteridine derivatives are suitable as phosphodiesterase inhibitors and therefore for the prophylaxis and/or therapy of thrombo-embolic, neuro-degenerating diseases, inflammatory diseases, asthmatic diseases, and hemato-oncological diseases.
[origin: WO03062240A1] The invention relates to compounds of general formula (I), in which R<sp>1</sp> represents a piperazino, p-phenylendiamine, 2,5-diazabicyclo-2.2.1-heptane, 2,5-diazabicyclo-2.2.2-octane, or 3,8-diazabicyclo-3.2.1-octane residue, each of which can be substituted with at least one substituent, R<sp>2</sp>, R<sp>4</sp>, which are identical, represent a pyrrolidino, thiazolidine, oxazolidine, or imidazolidine residue, each of which can be substituted with at least one substituent, R<sp>3</sp> represents an alkyl, alkoxy, alkylmercapto, or alkylamino residue, each of which can be substituted with at least one substituent, and the acid addition salts thereof. Said pteridine derivatives are suitable as phosphodiesterase inhibitors and therefore for the prophylaxis and/or therapy of thrombo-embolic, neuro-degenerating diseases, inflammatory diseases, asthmatic diseases, and hemato-oncological diseases.
IPC 1-7
IPC 8 full level
C07D 475/00 (2006.01); A61K 31/519 (2006.01); A61P 7/02 (2006.01); A61P 11/06 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07D 475/08 (2006.01)
CPC (source: EP US)
A61K 31/519 (2013.01 - EP US); A61P 7/02 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 475/08 (2013.01 - EP US)
Citation (search report)
See references of WO 03062240A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR
DOCDB simple family (publication)
WO 03062240 A1 20030731; CA 2511238 A1 20030731; DE 10202468 A1 20040930; EP 1467994 A1 20041020; JP 2005519912 A 20050707; US 2005054653 A1 20050310
DOCDB simple family (application)
EP 0300676 W 20030123; CA 2511238 A 20030123; DE 10202468 A 20020123; EP 03706378 A 20030123; JP 2003562117 A 20030123; US 89665904 A 20040722